Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 June;51(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 June;51(2):99-110

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

REWIEWS  MOLECULAR IMAGING IN PHARMACOLOGY


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 June;51(2):99-110

Copyright © 2007 EDIZIONI MINERVA MEDICA

language: English

Nuclear medicine applications in molecular imaging: 2007 update

Blankenberg F. G. 1, Strauss H. W. 2

1 Division of Pediatric Radiology F.G.B.-Department of Radiology Lucile Salter Packard Children’s Hospital, Stanford, CA, USA
2 Section of Nuclear Medicine H.W.S.-Department of Radiology Memorial Sloan Kettering Cancer Center, NY, USA


FULL TEXT  


This review examines several classes of radiolabeled agents, including analogs localizing in somatostatin, benzodiazepine and dopamine receptors; analogs of progesterone and estrogen; and agents localizing in lesions with hypoxia. It concludes the status of agents advocated for detecting angiogenesis and inflammation. The current clinical status of these agents, and their potential roles in diagnosis and treatment are discussed.

top of page

Publication History

Cite this article as

Corresponding author e-mail